Russian Heart Failure Journal 2006year Clinical hemodynamic effects of carvedilol; effects on lipid peroxidation and inflammation markers in patients with ischemic heart disease and chronic heart failure
Clinical hemodynamic effects of carvedilol; effects on lipid peroxidation and inflammation markers in patients with
ischemic heart disease and chronic heart failure
Zakirova A.N., Gabidullin R.R., Zakirova N.E.
Urgency. Along with activation of the RAAS and sympathetico-adrenal system, immune inflammatory responses and intensified processes of lipid peroxidation (LP) have been emphasized in the pathogenesis of chronic heart failure (CHF). This warrants the need in correction of the processes using β-adrenoblockers (BAB) which provide effects proven by evidence-based medicine. Aim of study was evaluating the effect of carvedilol on LV remodeling, exercise tolerance, LP processes and inflammation markers in patients with IHD and CHF. Materials and methods: Sixty-two IHD patients with CHF (LV EF <45%) were randomized to 2 groups and evaluated. The first group included 30 patients receiving carvedilol in addition to a standard therapy for 24 weeks; the second group included 32 patients receiving only the standard therapy. Evaluation included clinical instrumental (6-min walk test; echoCG), immunological (cytokines; vascular adhesion molecule) and biochemical (levels of primary and secondary LP products) methods. Results. It was shown that long-term carvedilol treatment improved the clinical condition and physical working ability of patients; slowed LV remodeling; inhibited expression of proinflammatory cytokines and vascular adhesion molecule; and depressed LP intensity.